rs121908427
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_001365088.1(SLC12A6):c.3031C>T(p.Arg1011Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000634 in 1,578,520 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_001365088.1 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SLC12A6 | NM_001365088.1 | c.3031C>T | p.Arg1011Ter | stop_gained | 23/26 | ENST00000354181.8 | NP_001352017.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLC12A6 | ENST00000354181.8 | c.3031C>T | p.Arg1011Ter | stop_gained | 23/26 | 1 | NM_001365088.1 | ENSP00000346112 | A1 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152176Hom.: 0 Cov.: 32
GnomAD4 exome AF: 0.00000631 AC: 9AN: 1426344Hom.: 0 Cov.: 26 AF XY: 0.00000843 AC XY: 6AN XY: 711802
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152176Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74344
ClinVar
Submissions by phenotype
Agenesis of the corpus callosum with peripheral neuropathy Pathogenic:6Other:1
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Nov 12, 2019 | NM_133647.1(SLC12A6):c.3031C>T(R1011*) is classified as pathogenic in the context of Andermann syndrome. Sources cited for classification include the following: PMID 12368912 and 17893295. Classification of NM_133647.1(SLC12A6):c.3031C>T(R1011*) is based on the following criteria: The variant causes a premature termination codon that is expected to be targeted by nonsense-mediated mRNA decay and is reported in individuals with the relevant phenotype. Please note: this variant was assessed in the context of healthy population screening. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Sep 25, 2007 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 28, 2017 | The SLC12A6 c.3031C>T (p.Arg1011Ter) variant is a stop-gained variant predicted to result in premature termination of the protein. The p.Arg1011Ter variant has been reported in at least three studies in which it is found in a homozygous state in a total of nine patients with hereditary motor and sensory neuropathy with agenesis of the corpus callosum from six families (three Turkish, two South African, and one Dutch) (Howard et al. 2002; Salin-Cantegrel et al. 2007; Degerliyurt et al. 2013). In the study by Salin-Cantegrel et al. (2007) haplotype analysis revealed the variant arose on two different haplotypes, one shared by the Turkish families, and one shared by the Afrikaner/Dutch families. Control data are not available for this variant which has been reported at a frequency of 0.00002 in the European (non-Finnish) population, however this is based on one allele only in a region of good sequence coverage so the variant is presumed to be rare. Functional studies using a Xenopus oocyte flux assay demonstrated that the p.Arg1011Ter variant abolished transporter activity (Salin-Cantegrel et al. 2007). The last 30 amino acids of the SLC12A6 protein are highly conserved and the sequence is virtually identical across species including mammals, D. melanogaster, and C. elegans (Howard et al. 2002). Based on the evidence and the potential impact of stop-gained variants, the p.Arg1011Ter variant is classified as pathogenic for hereditary motor and sensory neuropathy with agenesis of the corpus callosum. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jan 05, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 15, 2021 | - - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
not provided Pathogenic:2
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics, Academic Medical Center | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 09, 2022 | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. ClinVar contains an entry for this variant (Variation ID: 5326). This premature translational stop signal has been observed in individuals with agenesis of the corpus callosum with peripheral neuropathy (PMID: 12368912, 24341143). This variant is present in population databases (rs121908427, gnomAD 0.0009%). This sequence change creates a premature translational stop signal (p.Arg1011*) in the SLC12A6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLC12A6 are known to be pathogenic (PMID: 12368912, 16606917). - |
See cases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Mar 02, 2020 | ACMG classification criteria: PVS1, PS3, PS4, PM2, PM3 - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at